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A B S T R A C T
Malaria is a serious and sometimes fatal disease caused by an intraerythrocytic parasite, and is
commonly seen in developing countries. Approximately 1500 cases of malaria are diagnosed in the
United States each year, mostly in travelers and immigrants returning from endemic areas [1]. There are
many different regimens used to treat malaria, some of which are not approved in the USA. The side
effects of these medications may not be familiar to physicians in the USA. We report a case of a returning
traveler from Nigeria presenting with fever and hemolytic anemia caused by a delayed response to
artesunate given 3 weeks earlier while in Nigeria. To our knowledge, there are few cases reported in the
United States of hemolytic anemia secondary to artesunate therapy [2].
 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Malaria is a serious and sometimes fatal disease caused by a
parasite, which is commonly seen in developing countries.[1]
Parenteral artesunate is the ﬁrst line treatment for severe malaria
worldwide, however it is not yet licensed in the United States
[3]. Therefore, side effects may not be familiar to physicians in the
USA. We report a case of a returning traveler with fever and
delayed hemolytic anemia from artesunate given while in Nigeria.
Case description
A 68 year old African American woman presented with a three
day history of fever to 102 8F, periods of intermittent confusion,
fatigue, anorexia, and myalgia. The patient was treated with
artesunate for malaria in Nigeria 3 weeks prior to admission. The
symptoms completely resolved 2 weeks after completing treat-
ment with artesunate. She returned to the USA 1 week before
presentation.
On physical examination, the patient appeared ill. The
temperature was 101.6 8F, with a pulse of 106 beats/min, blood
pressure of 125/80 and oxygen saturation of 99% on room air. The
sclerae were pale and icteric. Cardiopulmonary examination was
normal and there was no hepatosplenomegaly, skin rash or* Corresponding author. Tel.: +1 718 234 8111
E-mail address: jbertelle@maimonidesmed.org (J.S. Lahoud).
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4.0/).petechiae. Laboratory examination revealed a leukocyte count of
21,000/mL with 70% neutrophils, 23% lymphocytes, 4% monocytes
and 3% eosinophils, a hemoglobin of 8.4 g/dL which dropped to
7.0 on the ﬁfth day of hospitalization, and a platelet count of
306,000. The serum in the chemistry tube was grossly hemolyzed,
with a potassium of 15 mEq/L and normal renal function.
Hemolysis was noted on repeat specimens.
On the ﬁrst hospital day, the temperature was 102 8F, and the
patient was lethargic and confused. A CT scan of the head did not
reveal any intracranial pathology. Wright–Giemsa stain from
multiple blood samples did not reveal intraerythrocytic parasites.
However, the peripheral smear was remarkable for rouleaux
formation and erythrocytes with atypical diamond-shaped central
blanched pitting [Fig. 1]. Further laboratory testing on hospital day
2 revealed an indirect bilirubin of 3.2 mg/dL, total bilirubin 4.4 mg/
dL, LDH 965 IU/dL and haptoglobin 326 mg/dL (normal 43–212).
The anemia and hemolytic picture worsened over the next few
days, before improving [Table 1].
On hospital day 3, the patient was treated with hydroxychlor-
oquine, despite having several peripheral smears negative for
parasites. It was later discontinued because the patient developed
a diffuse puritic rash thought to be a hypersensitivity reaction. On
hospital day 5, the patient was treated with doxycycline. All
antimalarial drugs were discontinued by hospital day 7. The
patient’s hospital course was complicated by development of a
small pulmonary embolus. The patient was discharged to home on
hospital day 11 with oral anticoagulation for the pulmonary
embolus.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
Fig. 1. Peripheral smear reveals rouleaux formation and diamond-shaped blanched
pitting within some erythrocytes.
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Severe malaria remains a serious clinical condition with
considerable mortality. According to the World Health Organiza-
tion, there were an estimated 198 million cases of malaria
worldwide (range 124–283 million) in 2013, and an estimated
584,000 deaths (range 367,000–755,000). Ninety percent of all
malaria deaths occur in Africa. With an estimated 207 million
clinical cases of malaria each year and more than 600,000 malaria
related deaths, the burden of disease remains unacceptably high
[4].
Artesunate is a derivative of the ‘‘quing hao’’, or sweet
wormwood plant, which has been used worldwide for more than
20 years for the treatment of malaria. It inhibits parasite
metabolism and enhances the clearance of infected erythrocytes.
It is used as ﬁrst line therapy for severe malaria in sub Saharan
Africa and Southeast Asia, but is not yet licensed in the United
States. Although other agents are FDA-approved for the treatment
of uncomplicated malaria, intravenous quinidine gluconate is
currently the only non-oral drug that is FDA approved and
available to treat severe malaria in the United States. In 2007,
intravenous artesunate was only approved as an investigational
new drug (IND) protocol by the FDA in the United States [5]. There
have been 19 reported cases of delayed hemolytic anemia after
treatment of severe malaria with artesunate during 2010–2012.Table 1
Trend in blood counts and bilirubin during hospitalization.
Hospital day 1 2 3 4 5 
WBC (K/UL) 12.2 14.0 21.1 21.7 2
Hgb (gm/dL) 10.1 9.5 8.1 8.2 
Hct (%) 31.0 28.8 24.5 24.2 2
PLT (K/uL) 306 308 289 345 42
Tot bili (mg/dL) 3.0 4.4 
Ind bili (mg/dL) 2.2 3.2 
WBC: white blood cell count; Hgb: hemoglobin; Hct: hematocrit; PLT: platelet count; Worldwide, there have been 37 reported cases of hemolysis
associated with the use of artemisinin derivatives in the treatment
of severe malaria [2]. To our knowledge, there have been only two
similar cases of delayed hemolysis due to artesunate therapy
described in the United States [6].
Two distinct patterns of hemolysis after artesunate therapy
have been described: a delayed onset or a persistent pattern of
hemolysis [7]. Persistent hemolysis is deﬁned as continuing
hemolysis starting around day 7 of artemisinin treatment and
persisting beyond day 14. Delayed hemolysis typically occurs 2–3
weeks after completion of artesunate therapy, as in our patient. A
delayed hemolytic pattern is deﬁned by a decrease in hemoglobin
associated with a low haptoglobin or increase in LDH occurring at
least 7 days following artesunate treatment [7]. These latter
ﬁndings were demonstrated in our patient, and after reviewing the
clinical presentation and peripheral smear, it was determined that
fever and delayed hemolysis were more likely to have been
secondary to recent artesunate therapy in Nigeria.
The cause of hemolysis from artesunate remains unclear. One
proposed mechanism is a splenic process called pitting, a process
where artesunate exposed parasites are expelled from infected
erythrocytes in the spleen. The erythrocytes then reseal (instead of
lysing) and reenter circulation as pitted erythrocytes where they
have a shortened lifespan. The delayed clearance of these pitted
erythrocytes by the spleen may explain the features of post
artesunate delayed hemolysis [9]. The degree of initial parasitemia
increases the risk of this entity. A recent French study analyzed the
hematologic parameters of 123 travelers treated with arteusnate
for severe malaria. Among 60 nontransfused patients observed for
more than 8 days, 13 (22%) had delayed hemolysis [8].
The onset of hemolysis in the second or third week after
treatment means that it is most likely to occur after a patient has
been discharged from the hospital. Therefore, active screening for
this side effect is important.
Physicians should be aware of this delayed side effect in order to
prevent unnecessary further treatment of presumed malaria. There
is no speciﬁc treatment or antidote. CDC has amended the
artesunate IND protocol and now recommends that persons
treated for severe malaria with artesunate be followed for 4 weeks
after treatment and evaluated for hemolytic anemia [2]. Still, in
many parts of the world where malaria is endemic, artemisinin-
based drugs are considered miracle drugs for resistant malaria. A
multidisciplinary team approach is important for early diagnosis
and appropriate management of this clinical presentation.
Conclusion
In returning travelers from countries in which malaria is
endemic, physicians in the U.S.A. should be aware of delayed
hemolysis after artesunate therapy. Parenteral artesunate is only
released by the CDC when parenteral quinidine is contraindicated,
not tolerated or not available. Hemolysis probably results from
delayed clearance of once infected erythrocytes which continue to
circulate after artesunate has killed the parasites.6 7 8 9 10 11
5.2 23.9 23.9 21.8 21.1 18.9 17.4
7.7 7.7 7.2 7.3 7.6 7.2 7.7
2.8 23.8 21.1 21.7 22.7 21.5 22.8
3 463 504 525 561 522 545
0.8
0.5
Tot bili: total bilirubin; Ind bili: indirect bilirubin.
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